Please wait...
About This Project
OncoSynergy, Inc.
The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
Browse Other Projects on Experiment
Related Projects
Can we predict which lung injury patients will develop fibrosis?
Many patients recover from acute lung injury, while others develop life-threatening pulmonary fibrosis...
How do mechanical forces drive cancer cells across the basement membrane?
Cancer spread begins when invasive cells cross the basement membrane, but current models fail to capture...
Could non-tuberculous mycobacteria infections explain the high mortality rates among TB patients in Kilifi, Kenya?
Mortality rate is significantly higher among clinically diagnosed Tuberculosis (TB) patients than the ones...
